An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) to participate in fireside chat at JMP Securities Hematology and Oncology Summit. The clinical-stage biopharmaceutical company is developing small-molecule product candidates for serious diseases such as oncology, obesity, and NASH.
Positive
None.
Negative
None.
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit. Details are as follows:
JMP Securities Hematology and Oncology Summit Fireside Chat Date/Time: Wednesday, December 6, 2023 at 12:30 PM ET Location: Virtual
A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.
About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: www.ternspharma.com.
Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company developing small-molecule product candidates to address serious diseases, including oncology, obesity, and NASH.
The fireside chat is scheduled for Wednesday, December 6, 2023, at 12:30 PM ET.
The live webcast will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com.
The replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.
terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.
